English: Combination of two brain diagrams in one for comparison. In the left normal brain, in the right brain of a person with Alzheimer’s disease. Diagram of the brain of a person with Alzheimer’s Disease. Diagram of a normal brain. (Photo credit: Wikipedia)
Researchers at Yale School of Medicine have discovered a new drug compound that reverses the brain deficits of Alzheimer’s disease in an animal model.
Their findings are published in the Aug. 5 issue of the journal PLoS Biology.
The compound, TC-2153, inhibits the negative effects of a protein called STtriatal-Enriched tyrosine Phosphatase (STEP), which is key to regulating learning and memory. These cognitive functions are impaired in Alzheimer’s.
“Decreasing STEP levels reversed the effects of Alzheimer’s disease in mice,” said lead author Paul Lombroso, M.D., professor in the Yale Child Study Center and in the Departments of Neurobiology and Psychiatry at Yale School of Medicine.
Lombroso and co-authors studied thousands of small molecules, searching for those that would inhibit STEP activity. Once identified, those STEP-inhibiting compounds were tested in brain cells to examine how effectively they could halt the effects of STEP. They examined the most promising compound in a mouse model of Alzheimer’s disease, and found a reversal of deficits in several cognitive exercises that gauged the animals’ ability to remember previously seen objects.
Read more . . .
The Latest on: Alzheimer’s drug
via Google News
The Latest on: Alzheimer’s drug
- Coverage Launched on Co. in Alzheimer's Drug Spaceon May 18, 2022 at 12:13 pm
(PMN:TSX; ARFXF:OTCQB) recently garnered analyst coverage by Douglas Loe at Leede Jones Gable, as noted in a May 11th research note. The Canadian investment firm initiated coverage on ProMIS with a ...
- Major TBI Tied to Dementia; ALS Drug Shows Promise in Japan; Selma Blair's MSon May 17, 2022 at 12:33 pm
A French court ordered Sanofi to pay up to €450,000 in damages to a family whose child has a form of autism after prenatal exposure to the epilepsy drug valproate (Depakine), saying the drugmaker did ...
- Alzheimer’s Association says accelerated drug approvals necessary in search for treatmenton May 17, 2022 at 6:55 am
Medicare's decision to limit coverage for a controversial new Alzheimer's drug has prompted an outcry among Alzheimer's advocates. The drug is Aduhelm, and despite widespread enthusiasm for it among ...
- Coverage of Alzheimer’s drug Aduhelm limited due to concerns about effectiveness, safetyon May 16, 2022 at 6:43 am
Aduhelm, an expensive Alzheimer's drug, is fomenting controversy — and generating excitement for patients. The FDA approved it last summer. But Adulem’s results are the subject of intense debate — and ...
- Peschin: Medicare and its decision not to pay for an Alzheimer's drugon May 15, 2022 at 2:52 am
In this commentary, Sue Peschin reviews the reasoning behind a decision by Medicare not to pay for a promising Alzheimer's drug ...
- China’s Alzheimer’s Drug Derailed as Global Trial Terminatedon May 13, 2022 at 9:26 am
A global clinical trial of a drug that has been approved in China for treating Alzheimer’s disease was terminated because of a lack of funding and Covid-19 disruptions, the developer said.
- Will the FDA change how it vets treatments following the Alzheimer's drug debacle?on May 13, 2022 at 7:48 am
Nearly a year after the US Food and Drug Administration (FDA) gave the green light to a controversial drug to treat Alzheimer’s disease, lawmakers are attempting to amend the process that led to its ...
- Biogen Seeks Accelerated Approval for Second Alzheimer's Drugon May 12, 2022 at 4:32 am
Biogen Inc. and its Japanese development partner, Eisai, are looking to get their next Alzheimer's drug to market using the U.S. Food and Drug Administration's accelerated approval pathway — the same ...
- The Petri Dish: Biogen seeks accelerated approval for second Alzheimer's drugon May 12, 2022 at 2:24 am
Biogen Inc. and development partner Eisai are looking to get their next Alzheimer's drug to market using the FDA's accelerated approval pathway — the same route they used for controversy-laden Aduhelm ...
- Alzheimer’s Drugs Market is Set to Grow According to Latest Research Report Forecast 2017-2025on May 11, 2022 at 5:30 am
The Alzheimer’s drug development pipeline is characterized by an expanding array of symptomatic treatments and potential disease-modifying therapies in the Alzheimer’s drug market. Biopharmaceutical ...
via Bing News
2 Comments
kennard peterson
do they sell tcp2153 and cost thank you
innovation
Please contact the original author for further information.